Health Care & Life Sciences » Biotechnology | Voyager Therapeutics Inc.

Voyager Therapeutics Inc. | Mutual Funds

Mutual Funds that own Voyager Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BB Biotech AG
1,992,641
6.14%
1,992,641
1.04%
03/31/2018
Fidelity Select Biotechnology Portfolio
1,605,562
4.95%
0
0.38%
07/31/2018
SPDR S&P Biotech ETF
937,520
2.89%
2,412
0.35%
09/06/2018
Eventide Healthcare & Life Sciences Fund
703,425
2.17%
0
2.21%
06/29/2018
Vanguard Total Stock Market Index Fund
540,453
1.67%
0
0%
07/31/2018
iShares Russell 2000 ETF
448,956
1.38%
-240
0.02%
09/06/2018
iShares Nasdaq Biotechnology ETF
372,726
1.14%
-4,872
0.08%
09/06/2018
AXA Framlington Biotech Fund
268,689
0.83%
268,689
0.82%
02/28/2018
Vanguard Extended Market Index Fund
261,183
0.81%
0
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
204,443
0.63%
0
0.04%
09/06/2018

About Voyager Therapeutics

View Profile
Address
75 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.voyagertherapeutics.com
Updated 07/08/2019
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.